Page 445 - Binder2

This Chapter is a Blueprint

Chapter 8 is not about molecules. It’s about momentum.
It’s about how this next chapter of medicine moves from
prototype to paradigm.

We’ll explore:

• The ecosystem of startups, researchers, and
regulators trying to rebuild drug development from
the ground up.
• The policies and funding mechanisms that must
evolve to reward tolerance and durability.
• And the cultural shift that asks scientists,
entrepreneurs, and patients alike to demand more—
more trust, more transparency, more time with the
therapies they rely on.

Because the revolution isn’t just about what we can build.

It’s about what we’re willing to expect.

8.1 – The Ecosystem Awakens

For decades, the biologics industry operated under the
implicit assumption that tolerization was an unfortunate but
unavoidable consequence of protein-based therapies. The
system was optimized not for long-term durability, but for
short-term response and commercial velocity. That
assumption is now being challenged—not just by theorists
or critics, but by a new generation of innovators,

443